Assignee
BEIGENE LTD
KY·58 granted patents·66 pending applications·996 citations·filing 2013–2025
Top patents by PatentIndex Score
124 records- 0198US9834606B2Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2015·Granted Dec 5, 2017·66 cites·11 claims
- 0298US9217034B2Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2014·Granted Dec 22, 2015·55 cites·32 claims
- 0398US8735553B1Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2013·Granted May 27, 2014·583 cites·35 claims
- 0497US10570139B2Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulatorsBEIGENE LTD·Filed 2018·Granted Feb 25, 2020·24 cites·15 claims
- 0597US10519235B2Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2018·Granted Dec 31, 2019·16 cites·10 claims
- 0697US10005782B2Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulatorsBEIGENE LTD·Filed 2016·Granted Jun 26, 2018·23 cites·21 claims
- 0797US9556188B2Substituted imidazo[1,2-b]pyrazoles as bruton'S tyrosine kinase modulatorsBEIGENE LTD·Filed 2015·Granted Jan 31, 2017·24 cites·15 claims
- 0897US9447106B2Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulatorsBEIGENE LTD·Filed 2015·Granted Sep 20, 2016·30 cites·23 claims
- 0996US9988450B2Anti-PD1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2017·Granted Jun 5, 2018·22 cites·22 claims
- 1093US11512132B2Anti-PD-L1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2019·Granted Nov 29, 2022·10 cites·14 claims
- 1193US11203637B2Anti-Tim-3 antibodies and use thereofBEIGENE LTD·Filed 2017·Granted Dec 21, 2021·8 cites·29 claims
- 1293US10864203B2Combination of a PD-1 antagonist and a RAF inhibitor for treating cancerBEIGENE LTD·Filed 2017·Granted Dec 15, 2020·10 cites·13 claims
- 1393US10544225B2Anti-PD-L1 antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2015·Granted Jan 28, 2020·15 cites·12 claims
- 1492US12077536B2BCL-2 inhibitorsBEIGENE LTD·Filed 2022·Granted Sep 3, 2024·4 cites·23 claims
- 1592US11202782B2Treatment cancers using a combination comprising PARP inhibitorsBEIGENE LTD·Filed 2017·Granted Dec 21, 2021·9 cites·29 claims
- 1692US10112952B2Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitorsBEIGENE LTD·Filed 2017·Granted Oct 30, 2018·5 cites·17 claims
- 1790US9393232B2Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-onesBEIGENE LTD·Filed 2014·Granted Jul 19, 2016·15 cites·12 claims
- 1889US11420968B2Bcl-2 inhibitorsBEIGENE LTD·Filed 2019·Granted Aug 23, 2022·7 cites·39 claims
- 1987US11597768B2Immunotherapy for hepatocellular carcinomaBEIGENE LTD·Filed 2018·Granted Mar 7, 2023·7 cites·13 claims
- 2087US10501467B2Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitorsBEIGENE LTD·Filed 2018·Granted Dec 10, 2019·2 cites·17 claims
- 2187US9617273B2Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitorsBEIGENE LTD·Filed 2016·Granted Apr 11, 2017·6 cites·10 claims
- 2286US11393566B1Interoperable platform for reducing redundancy in medical database managementBEIGENE LTD·Filed 2021·Granted Jul 19, 2022·2 cites·20 claims
- 2386US10351559B2Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses thereforeBEIGENE LTD·Filed 2016·Granted Jul 16, 2019·2 cites·46 claims
- 2485US11555038B2Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereofBEIGENE LTD·Filed 2018·Granted Jan 17, 2023·7 cites·7 claims
- 2585US11220506B2Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitorsBEIGENE LTD·Filed 2018·Granted Jan 11, 2022·2 cites·22 claims
- 2685US10280163B25 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenasesBEIGENE LTD·Filed 2016·Granted May 7, 2019·5 cites·30 claims
- 2784US11534431B2Combination of a PD-1 antagonist and a RAF inhibitor for treating cancerBEIGENE LTD·Filed 2020·Granted Dec 27, 2022·1 cites·21 claims
- 2884US11377449B2BTK inhibitors with improved dual selectivityBEIGENE LTD·Filed 2018·Granted Jul 5, 2022·3 cites·22 claims
- 2983US12195449B23-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereofBEIGENE LTD·Filed 2024·Granted Jan 14, 2025·0 cites·17 claims
- 3083US11136323B2Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitorsBEIGENE LTD·Filed 2017·Granted Oct 5, 2021·2 cites·34 claims
- 3183US9920055B2Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitorsBEIGENE LTD·Filed 2017·Granted Mar 20, 2018·3 cites·20 claims
- 3282US9895376B2Fused tricyclic compounds as Raf kinase inhibitorsBEIGENE LTD·Filed 2016·Granted Feb 20, 2018·3 cites·17 claims
- 3382US9670203B2Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitorsBEIGENE LTD·Filed 2014·Granted Jun 6, 2017·4 cites·24 claims
- 3481US10208038B2Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitorsBEIGENE LTD·Filed 2018·Granted Feb 19, 2019·2 cites·27 claims
- 3581US2024150361A1IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORSBEIGENE LTD·Filed 2024·Application pending·0 cites
- 3680US10457680B2Process for preparing a PARP inhibitor, crystalline forms, and uses thereofBEIGENE LTD·Filed 2016·Granted Oct 29, 2019·3 cites·23 claims
- 3779US10899763B2Crystalline forms of salts of fused penta-cyclic dihydrodiazepinocarbazolones, and uses thereofBEIGENE LTD·Filed 2018·Granted Jan 26, 2021·1 cites·26 claims
- 3879US10647714B25 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenasesBEIGENE LTD·Filed 2019·Granted May 12, 2020·2 cites·29 claims
- 3979US10576087B2Fused tricyclic compounds as Raf kinase inhibitorsBEIGENE LTD·Filed 2018·Granted Mar 3, 2020·2 cites·16 claims
- 4078US2024376097A1BCL-2 InhibitorBEIGENE LTD·Filed 2024·Application pending·0 cites
- 4177US11472788B2Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenasesBEIGENE LTD·Filed 2018·Granted Oct 18, 2022·1 cites·7 claims
- 4277US11214616B2Anti-TIGIT antibodies and their use as therapeutics and diagnosticsBEIGENE LTD·Filed 2018·Granted Jan 4, 2022·1 cites·11 claims
- 4377US10562899B2Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitorsBEIGENE LTD·Filed 2019·Granted Feb 18, 2020·1 cites·27 claims
- 4477US2024376104A1Bcl-2 InhibitorsBEIGENE LTD·Filed 2024·Application pending·0 cites
- 4575US9670231B2Fused tricyclic amide compounds as multiple kinase inhibitorsBEIGENE LTD·Filed 2014·Granted Jun 6, 2017·6 cites·37 claims
- 4675US2024096462A1Interoperable platform for reducing redundancy in medical database managementBEIGENE LTD·Filed 2023·Application pending·0 cites
- 4774US12103974B2Anti-OX40 antibodies and methods of useBEIGENE LTD·Filed 2019·Granted Oct 1, 2024·1 cites·17 claims
- 4874US11875885B2Interoperable platform for reducing redundancy in medical database managementBEIGENE LTD·Filed 2023·Granted Jan 16, 2024·0 cites·20 claims
- 4973US11905294B2Imidazo[1,5-a]pyrazine derivatives as PI3Kδ inhibitorsBEIGENE LTD·Filed 2021·Granted Feb 20, 2024·0 cites·23 claims
- 5073US10882856B25 or 8-substituted imidazo [1,5-a] pyridines as selective inhibitors of indoleamine and/or tryptophane 2,3-dioxygenasesBEIGENE LTD·Filed 2017·Granted Jan 5, 2021·1 cites·33 claims
Showing the top 50 of 124 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BEIGENE LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →